A phase 1b/2, dose-escalation, randomized, multicenter study of maintenance (maint) ivaltinostat (ival) plus capecitabine (cap) or capecitabine monotherapy in patients (pts) with metastatic pancreatic adenocarcinoma (PDAC) whose disease has not progressed

Evan Justin Walker, Erkut Hasan Borazanci, Gehan Botrus, Christos Fountzilas, J. Randolph Hecht, Anup Kasi, Niharika B. Mettu, Shubham Pant, Glenn Michelson, Gene Cho, Sangsook Ahn Cho, Lorna Liganor, Andrew H. Ko. A phase 1b/2, dose-escalation, randomized, multicenter study of maintenance (maint) ivaltinostat (ival) plus capecitabine (cap) or capecitabine monotherapy in patients (pts) with metastatic pancreatic adenocarcinoma (PDAC) whose disease has not progressed on first-line FOLFIRINOX chemotherapy (CT). Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):tps4181-tps4181.

2022
https://researcherprofiles.org/profile/344527033

Evan Justin Walker, Erkut Hasan Borazanci, Gehan Botrus, Christos Fountzilas, J. Randolph Hecht, Anup Kasi, Niharika B. Mettu, Shubham Pant, Glenn Michelson, Gene Cho, Sangsook Ahn Cho, Lorna Liganor, Andrew H. Ko